Cancer stem cell-like cells from a single cell of oral squamous carcinoma cell lines
Creators
- 1. Department of Oral and Maxillofacial Surgery, University of Regensburg (Germany)
- 2. Department of Operative Dentistry and Periodontology, University of Regensburg (Germany)
- 3. Department of Gynecology and Obstetrics, University of Regensburg (Germany)
- 4. Institute of Pathology, University of Regensburg (Germany)
- 5. Department of Radiotherapy, University of Regensburg (Germany)
Description
Research highlights: → Four oral squamous cancer cell lines (OSCCL) were analyzed for cancer stem cells (CSCs). → Single cell derived colonies of OSCCL express CSC-marker CD133 differentially. → Monoclonal cell lines showed reduced sensitivity for Paclitaxel. → In situ CD133+ cells are slow cycling (Ki67-) indicating a reduced drug sensitivity. → CD133+ and CSC-like cells can be obtained from single colony forming cells of OSCCL. -- Abstract: Resistance of oral squamous cell carcinomas (OSCC) to conventional chemotherapy or radiation therapy might be due to cancer stem cells (CSCs). The development of novel anticancer drugs requires a simple method for the enrichment of CSCs. CSCs can be enriched from OSCC cell lines, for example, after cultivation in serum-free cell culture medium (SFM). In our study, we analyzed four OSCC cell lines for the presence of CSCs. CSC-like cells could not be enriched with SFM. However, cell lines obtained from holoclone colonies showed CSC-like properties such as a reduced rate of cell proliferation and a reduced sensitivity to Paclitaxel in comparison to cells from the parental lineage. Moreover, these cell lines differentially expressed the CSC-marker CD133, which is also upregulated in OSCC tissues. Interestingly, CD133+ cells in OSCC tissues expressed little to no Ki67, the cell proliferation marker that also indicates reduced drug sensitivity. Our study shows a method for the isolation of CSC-like cell lines from OSCC cell lines. These CSC-like cell lines could be new targets for the development of anticancer drugs under in vitro conditions.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.bbrc.2011.02.084Additional details
Identifiers
- DOI
- 10.1016/j.bbrc.2011.02.084;
- PII
- S0006-291X(11)00289-0;
Publishing Information
- Journal Title
- Biochemical and Biophysical Research Communications
- Journal Volume
- 407
- Journal Issue
- 1
- Journal Page Range
- p. 28-33
- ISSN
- 0006-291X
- CODEN
- BBRCA9
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 45025771
- Subject category
- S60: APPLIED LIFE SCIENCES;
- Descriptors DEI
- ANIMAL TISSUES; ANTINEOPLASTIC DRUGS; CARCINOMAS; CELL CULTURES; CELL PROLIFERATION; CHEMOTHERAPY; CULTIVATION; IN VITRO; RADIOSENSITIVITY; RADIOTHERAPY; STEM CELLS
- Descriptors DEC
- ANIMAL CELLS; BODY; DISEASES; DRUGS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; RADIOLOGY; SENSITIVITY; SOMATIC CELLS; THERAPY
Optional Information
- Copyright
- Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.